Abstract: Compositions and methods for the personalized and targeted therapeutic treatment of diseases and disorders, including the treatment of pain, inflammation, and infectious diseases in a subject. In particular, labeled synthetic cannabinoid therapeutic compositions are provided that include a conjugate of a synthetic cannabinoid compound, a chelator, and a label, that when coupled with imaging may be used to determine in real time optimal dosing and targeting of particular pathways and tissues to provide personalized therapies. Combination therapies are also provided that include one or more synthetic cannabinoid compound and at least one active pharmaceutical ingredient.
Abstract: The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein M is an alpha-emitting radionuclide.
Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.
Abstract: Compounds of Marlush formula (I) described in the claims are useful in diagnostic methods for detecting and/or identifying cells presenting PSMA. Disclosed are also methods for preparing the compounds.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 17, 2023
Assignees:
CANCER TARGETED TECHNOLOGY LLC, WASHINGTON STATE UNIVERSITY
Abstract: This disclosure provides a family of compounds that absorb and fluoresce in the short wave infrared region (SWIR, optionally 1000 nm to 1300 nm), including hydrophilic compounds that exhibit absorption and emission spectral profiles in aqueous solutions substantially similar to those observed in organic solvents such as methanol or DMSO. The compounds can be chemically linked to biomolecules including proteins, nucleic acids, and therapeutic small molecules. The compounds are useful for imaging in a variety of medical, biological and diagnostic applications, including SWIR in vivo imaging of regions of interest within a mammal.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
January 10, 2023
Assignee:
PerkinElmer Health Sciences, Inc.
Inventors:
Nara Narayanan, Kevin Groves, Guojie Ho
Abstract: 6-[18F]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]PSMA-1007 and [Al18F]HBED-CC-PSMA. Unexpectedly, the 6-[18F]fluoro-2-alkoxy and 6-[18F]fluoro-4-alkoxy substituted analogs showed significant differences in accumulation in PSMA expressing prostate tumor cells. Whereas the 2-alkoxy derivative showed cellular uptake values higher than [18F]DCFPyL, the cellular uptake of the corresponding 4-alkoxy substituted derivative was significantly lower. Furthermore, in vivo PET studies with 2-alkoxy-substituted probes demonstrated excellent visualization of PSMA positive ganglia with extremely high target to background ratio. In contrast, the 4-alkoxy substituted derivatives showed less favorable biodistribution with significantly lower uptake in PSMA positive tissues.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
January 3, 2023
Assignee:
Universität zu Köln
Inventors:
Bernd Neumaier, Boris Zlatopolskiy, Philipp Krapf, Raphael Richarz, Alexander Drzezga
Abstract: The present invention relates to radiolabeled compounds of formula I wherein either A, B, R1, R2, is labeled with a radionuclide selected from 3H, 11C and 18F and its use for imaging alpha synuclein and/or Abeta deposits in mammals.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
January 3, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Edilio Borroni, Luca Gobbi, Michael Honer, Martin Edelmann, Dale Mitchell, David Hardick, Wolfgang Schmidt, Christopher Steele, Mushtaq Mulla
Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
Type:
Grant
Filed:
February 4, 2022
Date of Patent:
January 3, 2023
Assignee:
RAYZEBIO, INC.
Inventors:
Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio
Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.
Abstract: The present invention provides a novel method for the preparation of 18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
Type:
Grant
Filed:
August 19, 2020
Date of Patent:
December 27, 2022
Assignee:
GE HEALTHCARE LIMITED
Inventors:
Knut Richard Dyrstad, Torild Wickstrom, Thanushan Rajanayagam, Kristine Romoren, Olav Ryan
Abstract: A nanoparticle for diagnostic, therapeutic, and/or theranostic applications includes a rod-shaped plant virus like particle (VLP), one or more gadolinium T1 contrast agents conjugated to an interior surface of the VLP, and a layer of polydopamine (PDA) coated over a portion of the exterior surface of the VLP.
Abstract: The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.
Abstract: Compositions comprising high levels of high specific activity copper-64, and process for preparing said compositions. The compositions comprise from about 2 Ci to about 15 Ci of copper-64 and have specific activities up to about 3800 mCi copper-64 per microgram of copper. The processes for preparing said compositions comprise bombarding a nickel-64 target with a low energy, high current proton beam, and purifying the copper-64 from other metals by a process comprising ion exchange chromatography or a process comprising a combination of extraction chromatography and ion exchange chromatography.
Type:
Grant
Filed:
September 3, 2021
Date of Patent:
December 6, 2022
Assignee:
CURIUM US LLC
Inventors:
David Pipes, Lauren Radford, William Uhland, Brian Regna, Craig Brunkhorst
Abstract: Provided herein are nanoparticle-lipid composite carriers as theranostic agents, particularly for diagnosis and/or treatment of cancers and related diseases and conditions. In particular embodiments, the carrier composites comprise a lipid core and an outer shell of functionalized nanoparticles (fNPs).
Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
Type:
Grant
Filed:
June 8, 2020
Date of Patent:
November 22, 2022
Assignee:
Genentech, Inc.
Inventors:
Jan Marik, Joseph P. Lyssikatos, Simon Williams
Abstract: The present invention provides a novel method for the preparation of 18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
November 22, 2022
Assignee:
GE HEALTHCARE LIMITED
Inventors:
Torild Wickstrom, Anders Svadberg, Ole Kristian Hjelstuen, Dag M Evje, Liane Ochsenfeld
Abstract: The invention provides a novel class of MRI contrast agents based on biogenic hemin and compositions and methods of preparation and use thereof.
Abstract: A photosensitizer and derivative, application thereof. The photosensitizer has the structure of general formula I, wherein X is S or Se, Y is organic or inorganic ion, R1 and R2 are independently selected from H, alkyl, alkoxy, alkyl amido, alkyl azide and the like; R3 is selected from H, alkyl, alkoxy, amino sulfonyl, hydroxyl, carboxyl and the like, and L1 is a linker selected from —(CH2)n1— or —(CH2CH2O)n2—. The derivatives are molecular medicines with drug molecules of anticancer and chemotherapy or tumor targeting function connected to the said photosensitizer. The photosensitizer has excellent near infrared characteristics and low dark toxicity and is used in the field of photodynamic tumor therapy. The introduction of benzophenothiazine or benzophenoselenazine into derivatives with tumor-targeting function could improve the specific uptake of photosensitizer in tumor tissues.
Type:
Grant
Filed:
November 24, 2017
Date of Patent:
November 22, 2022
Assignees:
DALIAN UNIVERSITY OF TECHNOLOGY, DALIAN CHROMAS BIOSCTENCE CO., LTD
Inventors:
Xiaojun Peng, Mingle Li, Jiangli Fan, Qichao Yao, Jianjun Du, Saran Long, Jingyun Wang
Abstract: The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
November 22, 2022
Assignee:
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
Inventors:
Jung-Joon Min, Dong-Yeon Kim, Ayoung Pyo
Abstract: A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
November 22, 2022
Assignees:
PROVINCIAL HEALTH SERVICES AUTHORITY, THE UNIVERSITY OF BRITISH COLUMBIA
Inventors:
Kuo-Shyan Lin, François Bénard, Hsiou-Ting Kuo, Zhengxing Zhang, David Perrin